Journal of Hematology & Thromboembolic Diseases
Open Access

Soheir Adam

Publications

• Research Article
  Validation of a Scoring System for Prediction of Clinical Outcome in the Offlabel Use of Recombinant Factor VIIa
  Author(s): Galila Zaher, Soheir Adam, Fatima Azher, Salwa Hindawi, Ghazi DamanhouriGalila Zaher, Soheir Adam, Fatima Azher, Salwa Hindawi, Ghazi Damanhouri
  
  Background and Objectives: Recombinant factor VIIa (rFVIIa) is approved for treatment of inhibitors in hemophilia but has also been used for numerous off-label indications. Type of study: This study aims to validate a modified Biss scoring system in patients who received recombinant factor rFVIIa in Jeddah, Saudi Arabia. Materials and Methods: We included 70 patients who received rFVIIa for off-label indications over 12 months. Characteristics of survivor and non-survivor groups were compared including demographics, laboratory and clinical data. Using a modified Biss prognostic scoring system, based on the original scoring system used by Biss and Hanley, patients were divided into low (<1), intermediate (1-2) and high (≥3) score groups. Results: The mean age of patients was 46.1(±18.6) years. The most common off-label indications for rFVIIa treatment were to control blee.. View More»
  DOI: 10.4172/2329-8790.1000S1003

  Abstract PDF

Relevant Topics